[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Kim GM, Jeung HC, Kim D, Kim JH, Yoon SH, Jung ES, Shin SJ: A case of combined hepatocellular-cholangiocarcinoma with favorable response to systemic chemotherapy. Cancer Res Treat; 2010 Dec;42(4):235-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of combined hepatocellular-cholangiocarcinoma with favorable response to systemic chemotherapy.
  • Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare form of primary liver cancer composed of cells with histopathologic features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC).
  • Because of its low incidence, the information on clinical outcomes of cHCC-CC is very limited and there are no published reports describing non-surgical treatment options for cHCC-CC.
  • We report a case of cHCC-CC exhibiting a favorable response to systemic chemotherapy with doxorubicin and cisplatin.
  • A 62-year-old man who recurred after a right lobectomy for cHCC-CC received sorafenib for palliative systemic therapy, but follow up imaging studies showed disease progression.
  • He received 2nd line chemotherapy with doxorubicin at 60 mg/m(2) together with cisplatin at 70 mg/m(2).
  • After 2 cycles of chemotherapy, a computed tomography scan of the chest showed markedly decreased size and number of the multiple lung metastases.
  • After completing 8 cycles of 2nd line therapy, we changed the regimen to a fluorouracil (5-FU) mono therapy because of the toxicities associated with doxorubicin and cisplatin.
  • To date, the patient has completed his 15th cycle of 5-FU mono therapy with the disease status remaining stable during 18 months of follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nihon Rinsho. 2001 Oct;59 Suppl 6:401-5 [11761981.001]
  • [Cites] Ann Surg Oncol. 2009 Mar;16(3):623-9 [19130133.001]
  • [Cites] Gut. 2002 May;50(5):733-9 [11950826.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jun;33(6):283-7 [12913082.001]
  • [Cites] Am J Surg. 2005 Jan;189(1):120-5 [15701504.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(6):537-42 [17139428.001]
  • [Cites] Cancer. 1985 Jan 1;55(1):124-35 [2578078.001]
  • [Cites] J Gastroenterol Hepatol. 1996 Aug;11(8):758-64 [8872774.001]
  • [Cites] Hepatol Res. 2005 May;32(1):52-7 [15888382.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Nov;33(12):1941-3 [17212153.001]
  • [Cites] World J Gastroenterol. 2007 Mar 14;13(10):1500-4 [17461440.001]
  • [Cites] Asian J Surg. 2007 Apr;30(2):143-6 [17475587.001]
  • [Cites] Am J Pathol. 1949 Jul;25(4):647-55 [18152860.001]
  • [Cites] Int J Clin Pract. 2008 Aug;62(8):1271-8 [18284443.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2040-6 [11932907.001]
  • (PMID = 21253326.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3021743
  • [Keywords] NOTNLM ; Cholangiocarcinoma / Cisplatin / Doxorubicin / Hepatocellular carcinoma
  •  go-up   go-down


2. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer II, Wolff RA, Charnsangavej C, Brown TD: Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer; 2004 Aug 1;101(3):578-86
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
  • BACKGROUND: The goal of the current study was to evaluate the efficacy and toxicity of capecitabine in patients with nonresectable hepatobiliary carcinoma.
  • METHODS: The authors performed a retrospective analysis of all patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or gallbladder carcinoma (GBC) who were ever treated with oral capecitabine.
  • The medical records of 116 patients with hepatobiliary carcinoma who were treated at The University of Texas M. D.
  • Treatment was repeated every 21 days.
  • Each patient received 1-15 treatment cycles.
  • The median survival times were 10.1 months (95% confidence interval [CI], 4.5-15.7 months) for patients with HCC, 8.1 months (95% CI, 7.4-8.9 months) for patients with CCA, and 9.9 months (95% CI, 4.4-15.4 months) for patients with GBC.
  • For all patients, response to treatment was positively correlated with survival and decline in tumor markers.
  • CONCLUSIONS: Capecitabine was found to be safe for patients with hepatobiliary carcinoma, including those with cirrhosis.
  • [MeSH-major] Bile Duct Neoplasms / drug therapy. Carcinoma, Hepatocellular / drug therapy. Cholangiocarcinoma / drug therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Gallbladder Neoplasms / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Bile Ducts, Intrahepatic. Capecitabine. Cohort Studies. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Fluorouracil / analogs & derivatives. Follow-Up Studies. Humans. Male. Multivariate Analysis. Probability. Proportional Hazards Models. Retrospective Studies. Survival Analysis. Treatment Outcome


3. Nakajima T, Takayama T, Miyanishi K, Nobuoka A, Hayashi T, Abe T, Kato J, Sakon K, Naniwa Y, Tanabe H, Niitsu Y: Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester. J Pharmacol Exp Ther; 2003 Sep;306(3):861-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester.
  • Cholangiocarcinoma is markedly resistant to chemotherapy and has a dismal prognosis, but its mechanism of drug resistance is unknown.
  • This study examines whether glutathione S-transferase-pi (GSTP1-1) is involved in resistance to anticancer drugs in cholangiocarcinoma and whether GSTP1-1-specific inhibitors can overcome this resistance.
  • First, immunohistochemical examination disclosed strong staining of all our 17 cholangiocarcinoma specimens for GSTP1-1, irrespective of histological type.
  • Transfection of the GSTP1-1 antisense expression vector into a human cholangiocarcinoma cell line (HuCCT1) apparently decreased its intracellular GSTP1-1 concentration, and the sensitivity of transfectants to adriamycin (ADR), cisplatin, and alkylating agents such as melphalan and 4-hydroxyperoxycyclophosphamide (4-HC) was increased significantly, compared with that of mock transfectants.
  • The IC50 value of ADR or 4-HC for HuCCT1 cells decreased greater by treatment with C16C2 in a dose-dependent manner, paralleling the decrease in GSTP1-1 activity, than that of ADR or 4-HC alone.
  • The antitumor activity of ADR or cyclophosphamide was clearly enhanced by combination therapy with C16C2 in a xenograft model.
  • In conclusion, our results demonstrated that GSTP1-1 is a resistance factor for anticancer drugs in cholangiocarcinoma and that C16C2, a GSTP1-1-specific inhibitor, is a potent agent against the resistance.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cholangiocarcinoma / pathology. Drug Resistance, Multiple. Glutathione Transferase / antagonists & inhibitors. Isoenzymes / antagonists & inhibitors. Oligopeptides / pharmacology
  • [MeSH-minor] Animals. Carcinoma, Hepatocellular / pathology. Disease Models, Animal. Drug Resistance, Neoplasm. Drug Screening Assays, Antitumor. Glutathione S-Transferase pi. Humans. Immunohistochemistry. Inhibitory Concentration 50. Liver Neoplasms / pathology. Mice. Mice, Nude. Neoplasm Transplantation. Neoplasms, Experimental / drug therapy. Neoplasms, Experimental / prevention & control. Tumor Cells, Cultured. Xenograft Model Antitumor Assays

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12805482.001).
  • [ISSN] 0022-3565
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Isoenzymes; 0 / O(1)-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-phenylglycine ethyl ester; 0 / Oligopeptides; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / Gstp1 protein, mouse
  •  go-up   go-down


Advertisement
4. Noda T, Nagano H, Marubashi S, Kobayashi S, Takeda Y, Murakami M, Tomimaru Y, Dono K, Umeshita K, Nakayama M, Shima T, Wakasa K, Monden M, Doki Y, Mori M: [A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2099-102
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy].
  • We report a case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combined intra-arterial chemotherapy.
  • A 63-year-old female was in hospital for treatment of hepatic tumor in left lobe with portal venous tumor thrombus.
  • She was treated by IFN-alpha/5-FU chemotherapy, and the tumor was significantly reduced.
  • For 28 months, the tumor was successfully treated by IFN-alpha/5-FU chemotherapy.
  • But, thereafter the abdominal computed tomography showed the tumor re-growth and invasion to the diaphragm.
  • The histological findings were consistent with combined hepatocellular and cholangiocarcinoma.
  • This case suggested that the growth of cancer cells without sensitivity to IFN-alpha/5-FU chemotherapy and the blood supply via the diaphragm led the relapse of IFN-alpha/5-FU chemotherapy.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / drug therapy. Diaphragm / pathology. Fluorouracil / therapeutic use. Interferon-alpha / therapeutic use. Liver Neoplasms / drug therapy. Muscle Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Infusions, Intra-Arterial. Middle Aged. Neoplasm Invasiveness / pathology. Tomography, X-Ray Computed. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106536.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / alpha-Fetoproteins; U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Hertl M, Cosimi AB: Liver transplantation for malignancy. Oncologist; 2005 Apr;10(4):269-81
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for malignancy.
  • Liver transplantation for hepatic malignancies has emerged from an exotic and desperate approach to a well-documented and proven treatment modality for these unfortunate patients.
  • Currently, <10% of all liver transplants performed are for hepatocellular cancer (HCC).
  • Similarly, liver transplantation for HCC in the adult population yields good results for patients whose tumor masses do not exceed the Milan criteria.
  • It remains to be determined whether patients with more extensive tumors can be reliably selected to benefit from the procedure.
  • Epitheloid hemangioendothelioma is also an appropriate indication for liver transplantation, unlike angiosarcoma.
  • Metastatic liver disease is not an indication for liver transplantation, with the exception of cases in which the primary is a neuroendocrine tumor, for which liver transplantation can result in long-term survival and even cure in a number of patients.
  • And finally, while gallbladder cancers are never an indication for liver transplantation, rare cases of cholangiocellular cancer might qualify if aggressive combination therapies, including chemotherapy and radiotherapy followed by OLT, are carried through.
  • Survival in these selected patients can approach that for patients with cholestatic liver disease.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Cholangiocarcinoma / mortality. Cholangiocarcinoma / pathology. Cholangiocarcinoma / surgery. Hemangioendothelioma, Epithelioid / mortality. Hemangioendothelioma, Epithelioid / pathology. Hemangioendothelioma, Epithelioid / surgery. Hepatoblastoma / mortality. Hepatoblastoma / pathology. Hepatoblastoma / surgery. Humans. Medical Oncology / trends. Neoplasm Metastasis. Patient Selection. Survival Rate. Treatment Outcome. Waiting Lists

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15821247.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  •  go-up   go-down


6. Grossman EJ, Millis JM: Liver transplantation for non-hepatocellular carcinoma malignancy: Indications, limitations, and analysis of the current literature. Liver Transpl; 2010 Aug;16(8):930-42
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for non-hepatocellular carcinoma malignancy: Indications, limitations, and analysis of the current literature.
  • Orthotopic liver transplantation (OLT) is currently incorporated into the treatment regimens for specific nonhepatocellular malignancies.
  • For patients suffering from early-stage, unresectable hilar cholangiocarcinoma (CCA), OLT preceded by neoadjuvant radiotherapy has the potential to readily achieve a tumor-free margin, accomplish a radical resection, and treat underlying primary sclerosing cholangitis when present.
  • There exist subtle differences in the timing of chemotherapy between US and European centers; however, the long-term survival rate after transplantation ranges from 66% to 77%.
  • Fibrolamellar hepatocellular carcinoma is a distinct liver malignancy best treated by surgical resection.
  • In the treatment of either primary or metastatic hepatic sarcomas, unacceptable survival and recurrence rates currently prohibit the use of OLT.
  • [MeSH-major] Liver Neoplasms / therapy. Liver Transplantation / methods
  • [MeSH-minor] Aged. Cholangiocarcinoma / therapy. Hemangioendothelioma / therapy. Hepatoblastoma / therapy. Humans. Immunosuppressive Agents / therapeutic use. Liver / pathology. Medical Oncology / methods. Middle Aged. Neoplasm Metastasis. Neuroendocrine Tumors / therapy. Sarcoma / therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 AASLD.
  • (PMID = 20677284.001).
  • [ISSN] 1527-6473
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


7. Chen HW, Sheu JC, Lin WC, Tsang YM, Liu KL: Primary liver lymphoma in a patient with chronic hepatitis C. J Formos Med Assoc; 2006 Mar;105(3):242-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary liver lymphoma in a patient with chronic hepatitis C.
  • Primary liver lymphoma is a very rare disease and is frequently overlooked as a possible diagnosis.
  • We report the case of an asymptomatic middle-aged man with chronic hepatitis C who developed primary liver lymphoma (PLL).
  • A large solitary tumor in the left lobe of the liver was incidentally detected on routine ultrasound examination.
  • Imaging studies showed mixed iso- and hypoechogenicity with hypoechoic rim, hypodense in the pre-contrast phase and thick wall enhancement in the post-contrast phase on computed tomographic study, hypointensity on T1WI, and hyperintensity of the central portion and slightly higher intensity in the peripheral wall on T2WI.
  • These pictures were different from focal nodular hyperplasia, hepatocellular carcinoma, cholangiocarcinoma or metastases.
  • There was no tumor recurrence more than 4 years after operation and chemotherapy.
  • PLL should be included in the differential diagnosis of solitary hepatic tumor in patients who are hepatitis C virus-positive, and who have atypical imaging and no known malignancy or elevated tumor marker levels.

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520842.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


8. Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M: Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology; 2001 May-Jun;48(39):783-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas.
  • The efficacy of systemic chemotherapy in these patients is negligible and often, in particular in patients with hepatocellular carcinomas, the toxicity of chemotherapy outweighs the potential palliative effect of antineoplastic agents.
  • Gemcitabine is a new anticancer agent with a mild toxicity profile, which has demonstrated antineoplastic activity in many solid tumors.
  • Therefore we investigated the effect of gemcitabine in patients with advanced nonresectable hepatocellular and cholangiocellular carcinomas in a phase II study.
  • METHODOLOGY: Twenty-three patients with cholangiocellular carcinoma and 20 patients with hepatocellular carcinoma were enrolled into the study.
  • Eighteen of the 20 patients with hepatocellular carcinomas had liver cirrhosis.
  • The median number of gemcitabine administration was 15 (range, 3-37) in the group of patients with cholangiocellular carcinomas and 7.6 (range, 3-21) in the group of patients with hepatocellular carcinomas.
  • In the group of patients with hepatocellular carcinomas thrombocytopenia was the most frequent side effect (30% grade 3/4).
  • The overall response rate of hepatocellular carcinomas was only 5% and chemotherapy generally did not improve the tumor symptoms of the patients in this group.
  • Eleven patients with cholangiocellular carcinomas revealed tumor symptoms before the onset of gemcitabine treatment.
  • Seven of these patients developed a treatment related clinical benefit as defined as a relief of tumor symptoms or gain of weight.
  • CONCLUSIONS: Our results indicate that the treatment of cholangiocarcinomas with gemcitabine is effective and should be further evaluated in phase III studies.
  • In contrast, palliative chemotherapy with gemcitabine cannot be recommended in patients with hepatocellular carcinoma and liver cirrhosis.
  • [MeSH-major] Bile Duct Neoplasms / drug therapy. Carcinoma, Hepatocellular / drug therapy. Cholangiocarcinoma / drug therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11462924.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


9. Hamada A, Yamakado K, Nakatsuka A, Tanaka N, Takeda K: Repeated hepatic arterial infusion chemotherapy using an implanted port system in patients with unresectable malignant liver neoplasms: significant factors affecting early hepatic arterial occlusion. Oncol Rep; 2003 Nov-Dec;10(6):1821-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeated hepatic arterial infusion chemotherapy using an implanted port system in patients with unresectable malignant liver neoplasms: significant factors affecting early hepatic arterial occlusion.
  • The purpose of this study was to identify significant factors affecting early hepatic arterial occlusion in patients who received repeated hepatic arterial infusion chemotherapy using an implanted port system.
  • Eighty-five patients with unresectable liver neoplasms who underwent implantation of the port system were studied.
  • Arterial infusion chemotherapy was performed every 1-4 weeks.
  • The mean survival period was significantly worse in patients who experienced early arterial occlusion than those who did not (16 months vs. 26 months, p<0.05).
  • previous systemic chemotherapy.
  • Early arterial occlusion affects therapeutic effects and survival in patients who undergo arterial infusion chemotherapy with an implanted port.
  • [MeSH-major] Arterial Occlusive Diseases / drug therapy. Carcinoma, Hepatocellular / drug therapy. Cholangiocarcinoma / drug therapy. Hepatic Artery / pathology. Infusion Pumps, Implantable. Infusions, Intra-Arterial / methods. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colonic Neoplasms / pathology. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Risk. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14534703.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


10. Hatano H, Kobayashi S, Nagano H, Tomokuni A, Tomimaru Y, Murakami M, Marubashi S, Eguchi H, Takeda Y, Tanemura M, Wakasa K, Doki Y, Mori M: [A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2374-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus].
  • We report a case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus.
  • A 66-year-old man was diagnosed with hepatocellular carcinoma with Vp3 by abdominal enhanced CT.
  • He underwent a complete tumor resection and following interferon and 5-FU combined intra-arterial chemotherapy as an adjuvant setting.
  • The histological findings were consistent with combined hepatocellular and cholangiocarcinoma.
  • Then we started an oral fluoropyrimidine anticancer agent S-1, because the recurrence was suspected to be originated from the cholangiocarcinoma component.
  • In case of combined hepatocellular and cholangiocarcinoma, we need to create a treatment strategy against characteristics of both components.
  • [MeSH-major] Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / therapy. Cholangiocarcinoma / therapy. Liver Neoplasms / therapy. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Drug Combinations. Fluorouracil / administration & dosage. Hepatectomy. Humans. Interferons / administration & dosage. Male. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037427.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 9008-11-1 / Interferons; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Eguchi H, Nagano H, Sakon M, Miyamoto A, Kondo M, Arai I, Morimoto O, Dono K, Umeshita K, Nakamori S, Wakasa K, Monden M: A successful resection and long-term survival of a patient with intrahepatic recurrences of combined hepatocellular-cholangiocarcinoma: report of a case. Surg Today; 2002;32(8):742-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A successful resection and long-term survival of a patient with intrahepatic recurrences of combined hepatocellular-cholangiocarcinoma: report of a case.
  • Because of the low incidence rate of combined hepatocellular-cholangiocarcinoma (combined HCC-CC), the clinicopathological features of a recurrent tumor of this disease remain to be elucidated.
  • We describe a 47-year-old Japanese woman with a 5-cm diameter mass lesion in the liver.
  • A hepatectomy and dissection of the local lymph nodes were performed and a histological examination of the resected specimen showed combined HCC-CC.
  • After a follow-up of 15 months, intrahepatic recurrence was observed, and a hepatectomy was performed again followed by hepatic arterial infusion chemotherapy.
  • To improve the poor prognosis of combined HCC-CC, clinicopathological features of this disease and the therapy selection for recurrent tumors should be discussed.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / surgery. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Neoplasms, Multiple Primary / surgery
  • [MeSH-minor] Female. Hepatectomy. Humans. Middle Aged. Prognosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12181730.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Shimizu J, Hayashi S, Dono K, Yasumoto T, Zenitani M, Munakata K, Watanabe N, Takamoto K, Kagawa Y, Hata T, Kawanishi K, Ikeda K, Fujita J, Akagi K, Kitada M, Shimano T: [A case report of combined hepatocellular-cholangiocarcinoma whose lymph node recurrence effectively treated with UFT]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2380-2
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of combined hepatocellular-cholangiocarcinoma whose lymph node recurrence effectively treated with UFT].
  • Primary liver cancer with lymph node metastasis was recognized as poor prognosis.
  • A 74-year-old man with a huge mass lesion in the right liver with para Aortic lymph node metastasis admitted our hospital in April 2007.
  • A histological examination of the resected specimen showed a combined hepatocellular-cholangiocarcinoma with three lymph node metastasis.
  • Computed tomography(CT)revealed intra hepatic metastasis (S3) and right adrenal grand metastasis 5 months after surgery.
  • [MeSH-major] Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / drug therapy. Cholangiocarcinoma / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Lymphatic Metastasis / pathology
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Embolization, Therapeutic. Humans. Male. Neoplasm Recurrence, Local. Tegafur / administration & dosage. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037429.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil
  •  go-up   go-down


13. Marin JJ, Romero MR, Briz O: Molecular bases of liver cancer refractoriness to pharmacological treatment. Curr Med Chem; 2010;17(8):709-40
Hazardous Substances Data Bank. PODOFILOX .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular bases of liver cancer refractoriness to pharmacological treatment.
  • Hepatocellular carcinoma and cholangiocarcinoma are the two most important primary malignancies of the liver.
  • These are among the tumours with the lowest response to pharmacological treatment based on currently available drugs.
  • This is due either to the existence of refractoriness of the initial tumour or to the ability of cancer cells to develop chemoresistance during treatment.
  • Liver cancers share some of the mechanisms responsible for drug refractoriness with other types of tumours, such as a reduction in drug uptake; enhanced drug export; intracellular inactivation of the active agent; alteration of the molecular target; an increase in the activity of the target route to be inhibited, or the appearance or stimulation of alternative routes; enhanced repair of drug-induced modifications in the target molecules, and the activation/ inhibition of intracellular signalling pathways, all of which lead to a negative balance between the apoptosis/survival of tumour cells.
  • The aim of the present article is to review how these mechanisms of chemoresistance affect the different families of drugs that are being or have been used to treat hepatocellular carcinoma and cholangiocarcinoma.
  • A better understanding of the molecular bases of drug refractoriness is needed in order to develop novel drugs or pharmacological strategies aimed at overcoming resistance to anticancer agents.
  • [MeSH-major] Liver Neoplasms / drug therapy
  • [MeSH-minor] ATP-Binding Cassette Transporters / antagonists & inhibitors. ATP-Binding Cassette Transporters / metabolism. Anthracyclines / chemistry. Anthracyclines / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Coordination Complexes / chemistry. Coordination Complexes / therapeutic use. Drug Resistance, Neoplasm. Humans. Podophyllotoxin / chemistry. Podophyllotoxin / therapeutic use. Protein Kinase Inhibitors / chemistry. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / chemistry. Pyrimidines / therapeutic use

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20088759.001).
  • [ISSN] 1875-533X
  • [Journal-full-title] Current medicinal chemistry
  • [ISO-abbreviation] Curr. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Transporters; 0 / Anthracyclines; 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Coordination Complexes; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; L36H50F353 / Podophyllotoxin
  • [Number-of-references] 339
  •  go-up   go-down


14. Wall WJ: Liver transplantation for hepatic and biliary malignancy. Semin Liver Dis; 2000;20(4):425-36
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for hepatic and biliary malignancy.
  • The treatment of liver cancer by transplantation has evolved into a process of selecting early stage tumors that have a high likelihood of cure.
  • Carefully selected cirrhotic patients with early hepatocellular cancer (< or = 5 cm. diameter and single; < or = 3 cm. diameter if multiple and 3 or fewer lesions; no vascular invasion) have 5-year actuarial survival rates of approximately 75% after transplantation.
  • Adjuvant and neoadjuvant chemotherapy became part of treatment protocols in many centers at the same time that more stringent criteria for transplant candidacy were applied to patients with cancer, making it difficult to attribute improved results to the chemotherapy.
  • Nevertheless, neoadjuvant chemoembolization for hepatocellular cancer is logical for patients who may wait long periods before receiving transplants.
  • Hepatoblastoma in children can respond very favorably to chemotherapy combined with transplantation.
  • Cholangiocarcinoma remains a dreadful malignancy.
  • The rare cases of insitu cholangiocarcioma in patients who receive transplants for sclerosing cholangitis can be cured, but known cholangiocarcinoma has an exceedingly high rate of recurrence after transplantation alone.
  • Recent work combining chemotherapy and radiation with transplantation has not had dramatic success at improving cure rates.
  • Patients with metastatic neuroendocrine tumors of the liver can receive good palliation by transplantation, but the majority of patients eventually develop recurrent cancer.
  • [MeSH-major] Biliary Tract Neoplasms / therapy. Carcinoma, Hepatocellular / therapy. Cholangiocarcinoma / therapy. Liver Neoplasms / therapy. Liver Transplantation. Neuroendocrine Tumors / therapy
  • [MeSH-minor] Chemoembolization, Therapeutic. Combined Modality Therapy. Humans. Neoplasm Recurrence, Local. Palliative Care. Patient Selection. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11200413.001).
  • [ISSN] 0272-8087
  • [Journal-full-title] Seminars in liver disease
  • [ISO-abbreviation] Semin. Liver Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 95
  •  go-up   go-down


15. Malek NP, Greten T, Kubicka S: [Systemic treatment of liver and biliary tumors]. Internist (Berl); 2007 Jan;48(1):46-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Systemic treatment of liver and biliary tumors].
  • [Transliterated title] Systemische Therapie von Leber- und Gallenwegstumoren.
  • Hepatocellular carcinoma (HCC) is generally difficult to treat.
  • This is primarily due to the reduced liver function of most patients and the low sensitivity of liver cancer cells to chemotherapy.
  • Molecular therapies might represent an improvement in the systemic treatment of patients with HCC.
  • In addition to anti-angiogenic drugs, compounds which interfere with specific signal transduction cascades have shown promising results in smaller trials.
  • There are only limited numbers of studies about the systemic treatment options for biliary cancers.
  • In the absence of larger clinical phase III trials, no standard chemotherapy for biliary cancers exists today.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / drug therapy. Cholangiocarcinoma / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials, Phase III as Topic. Drug Delivery Systems. Drug Resistance, Neoplasm. Humans. Signal Transduction / drug effects

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 2005 Apr;39(4):333-8 [15758629.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):886-91 [11286466.001]
  • [Cites] Gut. 1998 Mar;42(3):442-7 [9577356.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2332-8 [15800324.001]
  • [Cites] J Gastroenterol. 2005 Mar;40(3):225-35 [15830281.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6657-63 [16170173.001]
  • [Cites] Hepatology. 2003 Feb;37(2):429-42 [12540794.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1474-84 [15196530.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4293-300 [16908937.001]
  • [Cites] J Clin Oncol. 2003 Feb 1;21(3):421-7 [12560429.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1898-903 [16622265.001]
  • (PMID = 17177032.001).
  • [ISSN] 0020-9554
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents
  •  go-up   go-down


16. Hayashi H, Beppu T, Ishiko T, Mizumoto T, Masuda T, Okabe K, Baba Y, Okabe H, Takamori H, Kanemitsu K, Hiroto M, Baba H: [A 42-month disease free survival case of combined hepatocellular-cholangiocarcinoma with lymph node metastases treated with multimodal therapy]. Gan To Kagaku Ryoho; 2006 Nov;33(12):1941-3
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A 42-month disease free survival case of combined hepatocellular-cholangiocarcinoma with lymph node metastases treated with multimodal therapy].
  • Combined hepatocellular and cholangiocarcinoma (HCC-CC) is a rare type of liver cancer.
  • We herein report a case of HCC-CC with lymph node metastases treated by multimodality therapy.
  • A 52-year-old man with a 9 cm diameter mass lesion in the liver was admitted to our hospital.
  • The tumor was diagnosed as peripheral type of cholangiocarcinoma.
  • An accumulation pattern of lipiodol after TACE and an increase of serum alpha-fetoprotein led us to diagnosis of combined HCC-CC.
  • A three segmentectomies of the liver and dissection of the local lymph nodes were performed.
  • A histological examination of the resected specimen showed combined HCC-CC with lymph node metastases.
  • The final diagnosis was a mixed type of combined HCC-CC.
  • To improve a poor prognosis of combined HCC-CC, adjuvant chemotherapy with CDDP, 5 FU and radiation therapy were achieved.
  • [MeSH-major] Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / therapy. Cholangiocarcinoma / therapy. Liver Neoplasms / therapy. Lymphatic Metastasis. Neoplasms, Multiple Primary / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemoembolization, Therapeutic. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Hepatectomy. Humans. Immunohistochemistry. Keratin-19 / analysis. Keratin-7 / analysis. Lymph Node Excision. Middle Aged. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212153.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Keratin-19; 0 / Keratin-7; 0 / alpha-Fetoproteins; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Uenishi T, Hirohashi K, Haba T, Wakasa K, Kubo S, Shuto T, Tanaka H, Yamamoto T, Tanaka S, Kinoshita H: Portal thrombosis due to intrahepatic cholangiocarcinoma following successful treatment for hepatocellular carcinoma. Hepatogastroenterology; 2003 Jul-Aug;50(52):1140-2
MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Portal thrombosis due to intrahepatic cholangiocarcinoma following successful treatment for hepatocellular carcinoma.
  • A 57-year-old man, who had undergone hepatic arterial infusion chemotherapy with right portal occlusion for hepatocellular carcinoma was admitted to our hospital because of severe abdominal pain.
  • Contrast-enhanced computed tomograms revealed that most areas of the liver were not enhanced, a finding suspicious for perfusion disturbance in the liver.
  • Arterial portograms revealed complete obstruction of the right portal vein and a small left branch of the portal vein.
  • Despite anticoagulant therapy with urokinase for portal vein thrombosis, the patient died from hepatorenal failure.
  • Autopsy revealed that cholangiocarcinoma occupied almost the entire parenchyma of the right lobe, although the treated hepatocellular carcinoma lesion was completely necrotic.
  • [MeSH-major] Bile Duct Neoplasms / complications. Bile Ducts, Intrahepatic. Cholangiocarcinoma / complications. Portal Vein. Venous Thrombosis / etiology
  • [MeSH-minor] Carcinoma, Hepatocellular / complications. Carcinoma, Hepatocellular / drug therapy. Fatal Outcome. Hepatic Artery / pathology. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasms, Multiple Primary / complications


18. Meyer CG, Penn I, James L: Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation; 2000 Apr 27;69(8):1633-7
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for cholangiocarcinoma: results in 207 patients.
  • BACKGROUND: Because of the high incidence of recurrent tumor, many surgeons have become disenchanted with transplantation as a treatment for cholangiocarcinoma.
  • METHODS: The Cincinnati Transplant Tumor Registry database was used to examine 207 patients who underwent liver transplantation for otherwise unresectable cholangiocarcinoma or cholangiohepatoma.
  • Specific factors evaluated included tumor size, presence of multiple nodules, evidence of tumor spread at surgery, and treatment with adjuvant chemotherapy and/or radiation therapy.
  • Tumor recurrence, and evidence of tumor spread at the time of surgery, were negative prognostic variables.
  • CONCLUSIONS: Because of the high rate of recurrent tumor and lack of positive prognostic variables, transplantation should seldom be used as a treatment for cholangiocarcinoma.
  • For transplantation to be a viable treatment in the future, more effective adjuvant therapies are necessary.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery. Liver Transplantation
  • [MeSH-minor] Adult. Aged. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10836374.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] UNITED STATES
  •  go-up   go-down


19. Popescu I, Ciurea S, Romanescu D, Boros M: Isolated resection of the caudate lobe: indications, technique and results. Hepatogastroenterology; 2008 May-Jun;55(84):831-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: This paper reports a series of 24 isolated caudate lobe resections (ICLR), performed for 13 benign tumors (10 hemangiomas, 2 focal nodular hyperplasias, 1 adenoma) and 11 malignant tumors (3 hepatocarcinomas, 1 peripheral cholangiocarcinoma and 7 metastatic - 5 colorectal carcinomas, 1 breast carcinoma, 1 adrenal carcinoma).
  • RESULTS: Complications occurred in 7 cases (3 bile leaks, 3 abdominal fluid collections and one liver failure leading to death).
  • From the 10 patients with malignant tumors who survived the operation, 7 developed recurrences: 2 intrahepatic, 1 retroperitoneal, 4 systemic.
  • Total vascular exclusion of the liver is routinely recommended in high dorsal resection.
  • Aggressive chemotherapy and follow-up are recommended.
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adenoma, Liver Cell / mortality. Adenoma, Liver Cell / pathology. Adenoma, Liver Cell / surgery. Adrenal Gland Neoplasms / mortality. Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / surgery. Adult. Bile Duct Neoplasms / mortality. Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / surgery. Breast Neoplasms / mortality. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / mortality. Cholangiocarcinoma / pathology. Cholangiocarcinoma / surgery. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Female. Focal Nodular Hyperplasia / mortality. Focal Nodular Hyperplasia / pathology. Focal Nodular Hyperplasia / surgery. Hemangioma / mortality. Hemangioma / pathology. Hemangioma / surgery. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Postoperative Complications / etiology. Postoperative Complications / mortality. Postoperative Complications / surgery. Reoperation. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705277.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


20. Menias CO, Surabhi VR, Prasad SR, Wang HL, Narra VR, Chintapalli KN: Mimics of cholangiocarcinoma: spectrum of disease. Radiographics; 2008 Jul-Aug;28(4):1115-29
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mimics of cholangiocarcinoma: spectrum of disease.
  • Cholangiocarcinoma is the second most common primary malignant hepatobiliary neoplasm, accounting for approximately 15% of liver cancers.
  • Diagnosis of cholangiocarcinoma is challenging and the prognosis is uniformly poor, with recurrence rates of 60%-90% after surgical resection.
  • A wide spectrum of neoplastic and nonneoplastic conditions of the biliary tract may masquerade as cholangiocarcinoma, adding to the complexity of management in patients suspected to have cholangiocarcinoma.
  • Mimics of cholangiocarcinoma constitute a heterogeneous group of entities that includes primary sclerosing cholangitis, recurrent pyogenic cholangitis, acquired immunodeficiency syndrome cholangiopathy, autoimmune pancreatitis, inflammatory pseudotumor, Mirizzi syndrome, xanthogranulomatous cholangitis, sarcoidosis, chemotherapy-induced sclerosis, hepatocellular carcinoma, metastases, melanoma, lymphoma, leukemia, and carcinoid tumors.
  • The imaging findings of these disparate entities are protean and may be indistinguishable from those of cholangiocarcinoma.
  • In most cases, a definitive diagnosis can be established only with histopathologic examination of a biopsy specimen.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic / pathology. Bile Ducts, Intrahepatic / radiography. Carcinoma / diagnosis. Cholangiocarcinoma / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18635632.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 69
  •  go-up   go-down


21. Cannavó SP, Borgia F, Adamo B, Guarneri B: Simultaneous development and parallel course of disseminated superficial porokeratosis and ovarian cancer: Coincidental association or true paraneoplastic syndrome? J Am Acad Dermatol; 2008 Apr;58(4):657-60
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The outbreak of disseminated superficial porokeratosis during the development of solid organ malignancies has been rarely reported in the literature in patients affected by hepatitis C virus-related hepatocellular carcinoma or by cholangiocarcinoma, which suggests a paraneoplastic nature of the cutaneous disease.
  • We report an unusual case of disseminated superficial porokeratosis in a patient affected by ovarian cancer, characterized by simultaneous onset and a parallel course of the two pathologies; there was good clinical response to chemotherapy, accompanied by a successful stop of disseminated superficial porokeratosis progression and gradual clearing of the keratotic lesions.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18258333.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Kanazawa A, Kubo S, Hirohashi K, Tanaka H, Shuto T, Takemura S, Yamamoto T, Sakabe K, Nishiguchi S: Two cases of intrahepatic cholangiocarcinoma detected after interferon therapy for chronic hepatitis C. Hepatogastroenterology; 2005 Nov-Dec;52(66):1869-73
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of intrahepatic cholangiocarcinoma detected after interferon therapy for chronic hepatitis C.
  • Recently, it has been suggested that hepatitis C virus infection plays a role in the pathogenesis of some intrahepatic cholangiocarcinomas (ICC).
  • We describe two patients with small ICC detected after interferon therapy for chronic hepatitis C.
  • Case 1 was diagnosed with ICC by preoperative biopsy and underwent anterior segmentectomy of the liver, while Case 2 was diagnosed with hepatocellular carcinoma preoperatively and the tumor was diagnosed as ICC after biopsy and microwave coagulonecrotic therapy.
  • It is important to monitor carefully for ICC as well as hepatocellular carcinoma in patients with chronic hepatitis C, even when interferon therapy has been carried out, since the outcome of treatment for small ICC is favorable.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic. Cholangiocarcinoma / diagnosis. Hepatitis C, Chronic / complications. Hepatitis C, Chronic / drug therapy. Interferon-alpha / therapeutic use
  • [MeSH-minor] Aged. Angiography. Biopsy, Needle. Catheter Ablation / methods. Female. Follow-Up Studies. Hepatectomy / methods. Humans. Immunohistochemistry. Male. Neoplasm Staging. Recombinant Proteins. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334796.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


23. Yen Y, Lim DW, Chung V, Morgan RJ, Leong LA, Shibata SI, Wagman LD, Marx H, Chu PG, Longmate JA, Lenz HJ, Ramanathan RK, Belani CP, Gandara DR: Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial. Am J Clin Oncol; 2008 Aug;31(4):317-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial.
  • PURPOSE: Prolonged survival for patients with unresectable hepatocellular carcinoma (HCC) is consistently reported at lower than 6 months.
  • The objective of this study was to determine the response rate, survival, time to progression, and toxicity in patients with poor prognosis HCC when treated with oxaliplatin.
  • EXPERIMENTAL DESIGN: Patients were required to have measurable recurrent, metastatic or unresectable HCC, and to have previously been exposed to no more than 2 prior chemotherapy regimens.
  • All patients received treatment with oxaliplatin 100 mg/m on day 1 and 15 as a 2-hour intravenous infusion and were pretreated with antiemetics.
  • Treatment was repeated every 28 days.
  • The median time to progression was 2 months; median survival was 6 months.
  • CONCLUSION: Single agent, oxaliplatin, has produced one partial response of good duration in 36 patients, but failed to meet the a priori criterion for promise in this trial.
  • Sixteen patients were observed to have stable disease with a well tolerated toxicity profile.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Organoplatinum Compounds / therapeutic use. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / secondary. Cholangiocarcinoma / drug therapy. Cholangiocarcinoma / secondary. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Clin Oncol. 2009 Feb;32(1):98. Wagman, Stephen D [corrected to Wagman, Lawrence D]
  • (PMID = 18845988.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin
  •  go-up   go-down


24. Ikeguchi M, Hirooka Y, Makino M, Kaibara N: Dihydropyrimidine dehydrogenase activity of cancerous and non-cancerous tissues in liver and large intestine. Oncol Rep; 2001 May-Jun;8(3):621-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dihydropyrimidine dehydrogenase activity of cancerous and non-cancerous tissues in liver and large intestine.
  • However, the therapeutic effect of 5-FU differs among patients.
  • The differences in the effectiveness of 5-FU are thought to be based on the different enzymatic activity which inactivates 5-FU of the host tissue.
  • 5-FU is catabolized to 2-fluoro-beta-alanine by dihydropyrimidine dehydrogenase (DPD) in liver and tumors.
  • In this study, we investigated the clinical significance of detecting DPD activity in patients with hepatocellular and colorectal carcinomas.
  • DPD activity in 63 hepatocellular carcinomas (HCCs), 3 cholangiocellular carcinomas (CCCs), 63 non-cancerous liver tissues adjacent to HCCs (N-HCCs), 6 normal livers (NLs), 189 colorectal carcinomas (CRCs), and 189 non-cancerous colorectal mucosas (N-CRCs) was analyzed by enzyme-linked immunosorbent assay (ELISA).
  • The mean DPD activities of these tissues were 209 +/- 187 Unit (U)/mg protein (HCC), 140 +/- 34 (CCC), 105 +/- 50 (N-HCC), 93 +/- 24 (NL), 58 +/- 45 (CRC), and 83 +/- 92 (N-CRC).
  • DPD activity of HCC was higher than that of CRC (p < 0.0001).
  • DPD activity of N-HCC was higher than that of N-CRC (p < 0.0001).
  • DPD activity of HCC was higher than that of N-HCC (p = 0.0014), on the other hand, DPD activity of CRC was lower than that of N-CRC (p < 0.0001).
  • In 20 CRC patients with synchronous liver metastasis, who underwent post-operative 5-FU chemotherapy through the hepatic artery, the mean survival time (29 months) of 9 patients with high DPD was not significantly different from that of 11 patients with low DPD (18 months, p = 0.3412).
  • Moreover, the DPD activity of primary CRC may not be a good indicator of the 5-FU chemosensitivity of synchronous liver metastasis.
  • [MeSH-major] Carcinoma, Hepatocellular / enzymology. Cholangiocarcinoma / enzymology. Colorectal Neoplasms / enzymology. Liver / enzymology. Liver Neoplasms / enzymology. Oxidoreductases / metabolism
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Dihydrouracil Dehydrogenase (NADP). Enzyme-Linked Immunosorbent Assay. Fluorouracil / therapeutic use. Humans. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11295091.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 1.- / Oxidoreductases; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); U3P01618RT / Fluorouracil
  •  go-up   go-down


25. Bhagat V, Javle M, Yu J, Agrawal A, Gibbs JF, Kuvshinoff B, Nava E, Iyer R: Combined hepatocholangiocarcinoma: case-series and review of literature. Int J Gastrointest Cancer; 2006;37(1):27-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined hepatocholangiocarcinoma: case-series and review of literature.
  • BACKGROUND AND AIM: Combined hepatocholangiocarcinoma (CHCC) is an infrequent primary hepatic malignancy with no clearly defined diagnostic criteria, poorly studied natural history, and no guidelines regarding therapy.
  • Eight cases were identified; histological and immunohistochemical criteria used for diagnosis were defined.
  • Abdominal pain (n = 6), hepatomegaly (n = 4), and elevated CA 19-9 >40 U/mL (n = 4/5) were frequent.
  • Median overall survival was significantly higher in patients who underwent potentially curative resection (23 mo, range 4-48+) compared with patients who underwent non-surgical therapies such as transcatheter arterial chemoembolization and chemotherapy (2 mo, range 1-8) (p = 0.0357, one-sided exact log-rank test).
  • Surgical resection and early stage at diagnosis predict longer survival.
  • [MeSH-major] Carcinoma, Hepatocellular / complications. Cholangiocarcinoma / complications. Liver Neoplasms / complications
  • [MeSH-minor] Aged. Aged, 80 and over. CA-19-9 Antigen / blood. Cholelithiasis / epidemiology. Female. Hepatitis B, Chronic / epidemiology. Humans. Male. Middle Aged. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1996 Oct;149(4):1167-75 [8863666.001]
  • [Cites] J Gastroenterol Hepatol. 1996 Aug;11(8):758-64 [8872774.001]
  • [Cites] J Hepatol. 2004 Aug;41(2):292-8 [15288479.001]
  • [Cites] Arch Surg. 2003 Jan;138(1):86-90 [12511158.001]
  • [Cites] Surg Clin North Am. 1999 Feb;79(1):43-57, viii [10073181.001]
  • [Cites] Liver. 1995 Feb;15(1):9-15 [7539881.001]
  • [Cites] Surg Clin North Am. 2004 Apr;84(2):643-57 [15062666.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):742-8 [9630182.001]
  • [Cites] Cancer. 1985 Jan 1;55(1):124-35 [2578078.001]
  • [Cites] Histopathology. 1989 May;14(5):503-13 [2472345.001]
  • [Cites] Natl Toxicol Program Tech Rep Ser. 2000 Jul;491:1-412 [12563349.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2332-8 [15800324.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jun;33(6):283-7 [12913082.001]
  • [Cites] AJR Am J Roentgenol. 2005 Apr;184(4):1157-62 [15788587.001]
  • [Cites] Korean J Gastroenterol. 2004 Jan;43(1):56-60 [14745254.001]
  • [Cites] Nihon Igaku Hoshasen Gakkai Zasshi. 1992 Feb 25;52(2):155-63 [1313961.001]
  • [Cites] Liver. 2002 Feb;22(1):43-50 [11906618.001]
  • [Cites] Jpn J Cancer Res. 1996 Oct;87(10):1056-62 [8957064.001]
  • [Cites] Oncol Rep. 2002 Jan-Feb;9(1):35-41 [11748452.001]
  • [Cites] Hepatogastroenterology. 2002 Nov-Dec;49(48):1487-90 [12397714.001]
  • [Cites] J Hepatol. 1999 Nov;31(5):965-6 [10580599.001]
  • [Cites] Southeast Asian J Trop Med Public Health. 1978 Jun;9(2):215-9 [214874.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;31 Suppl:S38-44 [1333907.001]
  • [Cites] Natl Toxicol Program Tech Rep Ser. 2002 May;(504):1-357 [12087420.001]
  • [Cites] J Gastroenterol Hepatol. 1998 Jan;13(1):34-40 [9737569.001]
  • [Cites] J Hepatol. 2004 Mar;40(3):472-7 [15123362.001]
  • [Cites] J Agric Food Chem. 2000 Aug;48(8):3620-32 [10956160.001]
  • [Cites] Am J Surg. 2005 Jan;189(1):120-5 [15701504.001]
  • [Cites] Chir Ital. 1999 Jan-Feb;51(1):1-7 [10514910.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):738-43 [11710692.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2040-6 [11932907.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 1992 Jun;30(6):342-5, 382 [1337514.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):115-25 [15192785.001]
  • [Cites] J Hepatol. 2004 Feb;40(2):298-304 [14739102.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):989-97 [12170085.001]
  • [Cites] Gan To Kagaku Ryoho. 1993 Feb;20(2):295-8 [8382037.001]
  • [Cites] Clin Liver Dis. 2005 May;9(2):191-211, v [15831268.001]
  • (PMID = 17290078.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  • [Number-of-references] 37
  •  go-up   go-down


26. Han S, Wang H, Xu L: [Diagnosis and surgical treatment of peripheral intrahepatic cholangiocarcinoma]. Zhonghua Wai Ke Za Zhi; 2001 Aug;39(8):590-2
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and surgical treatment of peripheral intrahepatic cholangiocarcinoma].
  • OBJECTIVE: To summarize the experience in diagnosis and surgical treatment of peripheral intrahepatic cholangiocarcinoma (PICC).
  • METHODS: Clinicopathological features, surgical treatment and prognosis of 20 patients with PICC treated in our hospital from 1970 to 1999 were retrospectively analyzed.
  • The diagnostic rates of ultrasound examination (BUS), CT, MRI and emission computerized tomography (ECT) were 90% (18/20), 94% (17/18), 100% (3/3) and 100% (4/4), respectively.
  • However, the liver lesions detected by these methods needed to be differentiated from hepatocellular carcinoma (HCC), metastatic neoplasm and liver cyst, etc.
  • The liver resection rates were 83% (11/12), 58% (7/12) and 33% (4/12), respectively.
  • Of the 4 patients who had survived for more than 5 years, 3 had a small liver carcinoma with a diameter less than or equal to 3 cm and one had large nodular liver carcinoma with intact capsule.
  • After operation, all the patients received selective hepatic artery perfusion chemotherapy.
  • CONCLUSION: PICC patients lack specific serum tumor marker can achieve good survival after early detection and curative resection with adjuvant therapies.
  • [MeSH-major] Cholangiocarcinoma / surgery. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Survival Rate. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11758193.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


27. Tsumura T, Takaki S, Aikata H, Kimura Y, Katamura Y, Azakami T, Kawaoka T, Tsuge M, Sanetou H, Waki K, Hiramatsu A, Imamura M, Kawakami Y, Takahashi S, Arihiro K, Chayama K: [Case of double cancer of the liver, cholangiocarcinoma and hepatocellular carcinoma detected in a patient with hepatitis C 13 years after diminution of HCV-RNA by interferon treatment]. Nihon Shokakibyo Gakkai Zasshi; 2009 May;106(5):674-83
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of double cancer of the liver, cholangiocarcinoma and hepatocellular carcinoma detected in a patient with hepatitis C 13 years after diminution of HCV-RNA by interferon treatment].
  • A 56-year-old man with chronic hepatitis C (HCV) was treated with interferon therapy and achieved sustained virological response (SVR) in 1993.
  • Thirteen years later, in 2006 two liver tumors, 35-mm and 11-mm in diameter respectively, were detected in liver segment 6.
  • Hepatic resection was performed, and pathologically one nodule was diagnosed as cholangiocellular carcinoma (CCC) and the other hepatocellular carcinoma (HCC).
  • Here, we report a rare case of double cancer (CCC and HCC) that developed 13 years after achieving SVR for HCV infection.
  • [MeSH-major] Carcinoma, Hepatocellular. Cholangiocarcinoma. Hepatitis C, Chronic / complications. Hepatitis C, Chronic / drug therapy. Interferon-alpha / administration & dosage. Liver Neoplasms. Neoplasms, Multiple Primary
  • [MeSH-minor] Biomarkers / blood. Hepacivirus / genetics. Humans. Male. Middle Aged. RNA, Viral / blood. Time Factors

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Hepatitis C (HCV).
  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19420872.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Interferon-alpha; 0 / RNA, Viral
  •  go-up   go-down


28. Pawlik TM, Scoggins CR, Thomas MB, Vauthey JN: Advances in the surgical management of liver malignancies. Cancer J; 2004 Mar-Apr;10(2):74-87
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the surgical management of liver malignancies.
  • Primary malignancies of the liver include tumors arising from the hepatocytes (hepatocellular carcinoma and the fibrolamellar variant) and the intrahepatic bile ducts (intrahepatic cholangiocarcinoma).
  • Hepatocellular carcinoma is the most common primary cancer of the liver and is a leading cause of death from cancer worldwide.
  • Although it is uncommon in the United States, the incidence of hepatocellular carcinoma is rising.
  • New clinical and pathological staging systems have allowed for the more accurate stratification of patients to more appropriately identify patients for resection, transplantation, and percutaneous ablation therapies.
  • A correlation between liver volume and surgical outcome has recently been demonstrated, with small liver remnant size being associated with increased morbidity.
  • Portal vein embolization has therefore been proposed as one way to induce hypertrophy of the anticipated liver remnant before resection.
  • More recently, systemic chemotherapy and chemoembolization have been investigated as both primary and neoadjuvant therapy.
  • Chemoimmunotherapy with 5-fluorouracil and interferon may be associated with a superior response rate in the fibrolamellar variant of hepatocellular carcinoma.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / surgery. Liver Neoplasms / surgery
  • [MeSH-minor] Decision Trees. Humans. Liver Cirrhosis / complications. Neoplasm Staging. Organ Size

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15130267.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 141
  •  go-up   go-down


29. Martin R, Jarnagin W: Intrahepatic cholangiocarcinoma. Current management. Minerva Chir; 2003 Aug;58(4):469-78
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrahepatic cholangiocarcinoma. Current management.
  • Peripheral/Intrahepatic Cholangiocarcinoma (IHC), a malignant epithelial tumor originating from the intrahepatic bile ducts, is the second most common primary liver cancer after hepatocellular carcinoma.
  • Unlike hepatocellular carcinoma, however, IHC is infrequently associated with chronic underlying liver disease.
  • Of the approximately 4000 patients seen at Memorial Sloan-Kettering Cancer Center with hepatic lesions since from 1995-2001, 7% had a diagnosis of cholangiocarcinoma and only 1% had IHC.
  • As a result, progress in elucidating the pathogenesis and clinical behavior of these tumors has been slow.
  • At present, complete resection is the only therapy that offers the possibility of long-term survival.
  • Single agent or combination chemotherapy and radiation therapy have not been shown to have a significant impact, either as primary treatment or as an adjuvant to resection.
  • This report reviews the relevant literature pertaining to IHC with emphasis on clinical presentation, radiologic evaluation, treatment and outcome.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Cholangiocarcinoma / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cholestasis, Intrahepatic / etiology. Comorbidity. Humans. Jaundice, Obstructive / etiology. Liver Diseases / epidemiology. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14603159.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 29
  •  go-up   go-down


30. Donckier V, Troisi R, Toungouz M, Colle I, Van Vlierberghe H, Jacquy C, Martiat P, Stordeur P, Zhou L, Boon N, Lambermont M, Schandené L, Van Laethem JL, Noens L, Gelin M, de Hemptinne B, Goldman M: Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft. Transpl Immunol; 2004 Sep-Oct;13(2):139-46
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft.
  • BACKGROUND AND AIM OF THE STUDY: The induction of transplantation tolerance, defined as the survival of a functioning allograft in the absence of continuing immunosuppressive therapy, would be a major advance.
  • We investigated the feasibility and safety of a protocol to induce tolerance to HLA mismatched living-donor liver graft by pre-transplant non-myeloablative conditioning followed by donor stem cells (SC) infusion, in patients with advanced liver cancers.
  • PATIENTS AND METHODS: Two patients with intrahepatic cancers who did not fulfill criteria for cadaver liver transplantation were included in the study.
  • Living-donor liver transplantation (LDLT) using the liver right lobe was performed after hematological reconstitution, respectively 40 and 55 days after donor stem cell infusion.
  • Immunosuppressive therapies were discontinued when liver graft function returned to normal.
  • RESULTS: The procedure could be completed in the two patients.
  • Immunosuppression was discontinued, respectively 90 and 28 days, after liver transplantation, without subsequent rejection episode.
  • In the two cases, liver function remained normal for the study period.
  • Mixed lymphocyte cultures, performed after immunosuppression withdrawal, demonstrated donor specific hyporesponsiveness in the first case, but in a context of global hyporeactivity in the two patients.
  • The first patient died from tumor recurrence 370 days after liver transplantation.
  • The second patient is alive, 270 days after liver transplantation, but with a suspicion of tumor relapse as indicated by the reappearance of tumor marker in blood.
  • CONCLUSION: In the two cases, acceptance of HLA mismatched living-donor liver graft was obtained after non-myeloablative conditioning and donor stem cell infusion.
  • Improving the rate of immune reconstitution appears as a priority to reduce the risk of tumor recurrence in such patients.
  • [MeSH-major] HLA Antigens / immunology. Immunosuppression / methods. Liver Transplantation / immunology. Peripheral Blood Stem Cell Transplantation. Transplantation Conditioning / methods. Transplantation, Homologous / immunology
  • [MeSH-minor] Antilymphocyte Serum / therapeutic use. Antineoplastic Agents / therapeutic use. Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / drug therapy. Cholangiocarcinoma / surgery. Combined Modality Therapy. Cyclophosphamide / pharmacology. Cyclophosphamide / therapeutic use. Fatal Outcome. Histocompatibility. Humans. Immunosuppressive Agents / therapeutic use. Interleukin-2 / biosynthesis. Interleukin-2 / genetics. Liver Neoplasms / surgery. Living Donors. Male. Middle Aged. Neoplasm Recurrence, Local. RNA, Messenger / biosynthesis. Sirolimus / therapeutic use. T-Lymphocytes / immunology. T-Lymphocytes / transplantation

  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15380544.001).
  • [ISSN] 0966-3274
  • [Journal-full-title] Transplant immunology
  • [ISO-abbreviation] Transpl. Immunol.
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antilymphocyte Serum; 0 / Antineoplastic Agents; 0 / HLA Antigens; 0 / Immunosuppressive Agents; 0 / Interleukin-2; 0 / RNA, Messenger; 8N3DW7272P / Cyclophosphamide; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


31. Tanida T, Tanemura M, Kobayashi S, Wada H, Marubashi S, Eguchi H, Takeda Y, Umeshita H, Mori M, Doki Y, Nagano H: [A case report--intrahepatic arterial infusion with CDDP and S-1 administration can elicit long-term survival for the patient with recurrenced intrahepatic cholangiocarcinoma after resection]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2729-31
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report--intrahepatic arterial infusion with CDDP and S-1 administration can elicit long-term survival for the patient with recurrenced intrahepatic cholangiocarcinoma after resection].
  • To cure intrahepatic cholangiocarcinoma (ICC), only a surgical resection is the potential treatment at present.
  • However, recurrence tumors in residual liver and/or distant organs even after curative surgery are commonly experienced in clinical course.
  • Unfortunately the potential treatment for this recurrent disease is not established at present.
  • Here, we report the prolonged survival case with recurrent ICC after hepatic resection followed by combined therapy of intrahepatic arterial infusion with CDDP and S-1 administration.
  • After that, liver tumor of 30 mm in diameter was detected in S1/8 by abdominal CT examination.
  • Subsequently, caudate lobectomy and partial resection of Segment 8 were performed under the diagnosis of Hepatocellular carcinoma in Osaka university hospital.
  • The pathological stage was T2N0M0, Stage II with moderately differentiated intrahepatic cholangiocarcinoma.
  • As the recurrence tumor was found in Segment 4 of residual liver, we started a treatment with intrahepatic arterial infusion with CDDP and S-1 administration, immediately.
  • These combined therapy displayed beneficial effects and a recurrent liver tumor was well controlled.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic. Cholangiocarcinoma / drug therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Drug Combinations. Female. Hepatic Artery. Humans. Infusions, Intra-Arterial. Neoplasm Recurrence, Local. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224694.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


32. Azoulay D, Andreani P, Maggi U, Salloum C, Perdigao F, Sebagh M, Lemoine A, Adam R, Castaing D: Combined liver resection and reconstruction of the supra-renal vena cava: the Paul Brousse experience. Ann Surg; 2006 Jul;244(1):80-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined liver resection and reconstruction of the supra-renal vena cava: the Paul Brousse experience.
  • BACKGROUND: Liver tumors with inferior vena cava (IVC) involvement may require combined resection of the liver and IVC.
  • This approach, with its high surgical risks and poor long-term prognosis, was precluded until the development of neoadjuvant chemotherapy, portal vein embolization, reinforced vascular prostheses, and technical advances in liver transplantation.
  • Indications for resection were: liver metastases (n = 9), cholangiocarcinoma (n = 8), hepatocellular carcinoma (n = 2), other cancers (n = 3).
  • The liver resections carried out included 18 first, 3 second, and one third hepatectomy.
  • Resection concerned 1 to 6 liver segments (median = 5.0).
  • Vascular control was achieved by vascular exclusion of the liver preserving the caval flow (n = 1), standard vascular exclusion of the liver (n = 12), in situ cold perfusion of the liver (n = 9).
  • The IVC was reconstructed with a ringed Gore-Tex tube graft (n = 10), primarily (n = 8), or by caval plasty (n = 4).
  • CONCLUSIONS: IVC resection and reconstruction combined with liver resection can be safely performed in selected patients.
  • The lack of alternative treatments and the spontaneous poor prognosis justify this approach, provided that surgery is carried out at a center specialized in both liver surgery and liver transplantation.
  • The development of adjuvant chemotherapy regimens is required to improve the long-term results of this salvage surgery.
  • [MeSH-major] Hepatectomy. Liver Neoplasms / surgery. Vena Cava, Inferior / surgery
  • [MeSH-minor] Adult. Aged. Blood Vessel Prosthesis Implantation. Female. Humans. Intraoperative Complications. Male. Middle Aged. Neoplasm Invasiveness. Postoperative Complications. Vascular Surgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2001 Mar;192(3):412-7 [11245386.001]
  • [Cites] Liver Transpl. 2001 Apr;7(4):359-62 [11303297.001]
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1455-60 [11677986.001]
  • [Cites] Semin Oncol. 2002 Apr;29(2):168-82 [11951215.001]
  • [Cites] Surgery. 1991 Feb;109(2):208-13 [1846984.001]
  • [Cites] Urology. 1992 Mar;39(3):285-8 [1546426.001]
  • [Cites] Am J Surg. 1992 Apr;163(4):387-94 [1373044.001]
  • [Cites] Can J Surg. 1994 Feb;37(1):59-61 [8306222.001]
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2049-53 [10615076.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):136-47 [10623704.001]
  • [Cites] J Vasc Surg. 2000 Feb;31(2):270-81 [10664496.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):480-6 [10749607.001]
  • [Cites] Surgery. 2000 May;127(5):520-7 [10819060.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] J Am Coll Surg. 2002 Jun;194(6):842-5 [12081078.001]
  • [Cites] Arch Surg. 2002 Dec;137(12):1332-9; discussion 1340 [12470093.001]
  • [Cites] J Am Coll Surg. 2003 Feb;196(2):243-9 [12595053.001]
  • [Cites] Arch Surg. 2003 Jun;138(6):624-30; discussion 630-1 [12799333.001]
  • [Cites] Ann Surg. 2003 Dec;238(6):871-83; discussion 883-4 [14631224.001]
  • [Cites] Surgery. 2003 Dec;134(6):989-93; discussion 993-4 [14668732.001]
  • [Cites] Ann Surg. 2004 May;239(5):712-9; discussion 719-21 [15082976.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S248-60 [15508091.001]
  • [Cites] Ann Surg. 1966 Feb;163(2):237-41 [4286023.001]
  • [Cites] Surg Gynecol Obstet. 1973 May;136(5):711-6 [4349727.001]
  • [Cites] Ann Surg. 1974 Oct;180(4):644-52 [4414545.001]
  • [Cites] Surg Gynecol Obstet. 1978 Nov;147(5):689-93 [715645.001]
  • [Cites] Surg Gynecol Obstet. 1980 Feb;150(2):208-14 [7352313.001]
  • [Cites] World J Surg. 1982 Jan;6(1):3-9 [7090393.001]
  • [Cites] Surgery. 1984 Mar;95(3):309-18 [6701787.001]
  • [Cites] Ann Surg. 1984 Oct;200(4):524-34 [6385876.001]
  • [Cites] J Vasc Surg. 1984 Nov;1(6):877-87 [6208388.001]
  • [Cites] Br J Surg. 1985 Jul;72(7):565-8 [2990629.001]
  • [Cites] Arch Surg. 1988 Aug;123(8):1021-2 [2969230.001]
  • [Cites] Acta Chir Scand. 1988 Jul-Aug;154(7-8):481-3 [2847455.001]
  • [Cites] Ann Surg. 1989 Jul;210(1):13-9 [2742411.001]
  • [Cites] J Vasc Surg. 1990 Sep;12(3):367-70 [2169006.001]
  • [Cites] Arch Surg. 1991 Jan;126(1):106-8 [1985628.001]
  • [Cites] J Am Coll Surg. 2000 Sep;191(3):244-50 [10989898.001]
  • [Cites] J Cardiothorac Vasc Anesth. 1994 Feb;8(1):58-60 [8167287.001]
  • [Cites] Surgery. 1994 Jun;115(6):740-4 [8197568.001]
  • [Cites] Br J Surg. 1994 Jun;81(6):845-6 [8044598.001]
  • [Cites] Arch Surg. 1995 Jul;130(7):793-7 [7611873.001]
  • [Cites] Br J Surg. 1995 Nov;82(11):1535-9 [8535812.001]
  • [Cites] Arch Surg. 1996 Apr;131(4):442-7 [8615734.001]
  • [Cites] Ann Surg. 1996 Aug;224(2):155-61 [8757378.001]
  • [Cites] Ann Surg. 1996 Oct;224(4):509-20; discussion 520-2 [8857855.001]
  • [Cites] Hepatology. 1996 Nov;24(5):1121-7 [8903386.001]
  • [Cites] Arch Surg. 1997 Oct;132(10):1104-9 [9336509.001]
  • [Cites] Liver Transpl Surg. 1996 Sep;2(5):354-61 [9346676.001]
  • [Cites] Eur J Surg Oncol. 1997 Dec;23(6):570-2 [9484935.001]
  • [Cites] Br J Surg. 1998 Apr;85(4):485-8 [9607528.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1407-12 [9807986.001]
  • [Cites] Arch Surg. 1999 Jan;134(1):30-5 [9927127.001]
  • [Cites] Surg Today. 1999;29(1):67-70 [9934835.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):1151-5 [10370683.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2532-40 [10375099.001]
  • [Cites] Ann Surg. 1999 Jul;230(1):24-30 [10400032.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):1052-61; discussion 1061-4 [15570210.001]
  • [Cites] J Am Coll Surg. 2005 Jan;200(1):57-63 [15631921.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):277-85 [15650638.001]
  • [Cites] Ann Surg. 2000 Nov;232(5):665-72 [11066138.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):777-85 [11088072.001]
  • [Cites] Eur J Surg Oncol. 2000 Dec;26(8):763-9 [11087642.001]
  • [Cites] J Am Coll Surg. 2001 Jan;192(1):137-41 [11192916.001]
  • [Cites] CA Cancer J Clin. 1999 Jul-Aug;49(4):231-55 [11198884.001]
  • [Cites] Ann Surg. 2001 Feb;233(2):242-9 [11176131.001]
  • [ErratumIn] Ann Surg. 2007 May;245(5):table of contents
  • (PMID = 16794392.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1570596
  •  go-up   go-down






Advertisement